Skip to main content
Clinical Trials/NL-OMON53966
NL-OMON53966
Not yet recruiting
Not Applicable

Evaluation of the safety, efficacy and cost-effectiveness of transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation in the Netherlands. - TRACE

Sint Antonius Ziekenhuis0 sites150 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Severe Tricuspid valve Regurgitation (TR) - severe leaking right heart valve
Sponsor
Sint Antonius Ziekenhuis
Enrollment
150
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. The patient is symptomatic (NYHA Functional Class II, III or ambulatory
  • class IV) despite Standard Of Care (SOC). The Central Screening Committee (CSC)
  • will assess whether the patient is receiving Standord Of Care (SOC), which for
  • TR is limited to symptomatic treatment with diuretics. The CSC will also ensure
  • that in case of the presence of atrial fibrillation, left sided heart valve
  • disease (not requiring intervention) or coronary artery disease, these
  • conditions are treated adequately with medication and/or intervention/device
  • 2\. The patient suffers from \>\= grade 3 isolated TR as determined by the
  • assessment of a qualifying TTE and 3DTEE and confirmed by the CSC, according to
  • PCR Tricuspid Focus Group consensus document (in press). Note: If cardiac

Exclusion Criteria

  • 1\. Systolic pulmonary artery pressure (sPAP) \> 70 mmHg or fixed pre\-capillary
  • pulmonary hypertension as assessed by RHC. Severe uncontrolled hypertension
  • Systolic Blood Pressure (SBP) \>\= 180 mmHg and/or Diastolic Blood Pressure (DBP)
  • \>\= 110 mmHg.
  • 2\. Any condition that would interfere with a TTVr procedure, such as prior
  • tricuspid valve repair or tricuspid valve leaflet anatomy which may preclude
  • device implantation (e.g. calcification in grasping area, a severe coaptation
  • defect of the tricuspid leaflets (non\-clippable), pacemaker or Implantable
  • Cardioverter Defibrillator (ICD) leads that would prevent appropriate placement
  • or visualization of TTVr devices, Ebstein Anomaly (normal annulus position, but

Outcomes

Primary Outcomes

Not specified

Similar Trials